Evidence map›Paper›PMID 40641595›Full record

ArticleBrain communications2025

Cerebrospinal fluid proteomic profiling of cognitively unimpaired individuals with suspected non-Alzheimer's disease pathophysiology.

Aurore Delvenne, Johan Gobom, Lianne M Reus, Valerija Dobricic, Mara Ten Kate, Suzanne E Schindler, Inez Ramakers, Betty M Tijms, Rik Vandenberghe, Jolien Schaeverbeke and 15 more

Abstract read
In one paragraph

Article in Brain communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Aurore DelvenneDepartment of Psychiatry and Neuropsychology, Alzheimer Centrum Limburg, School for Mental Health and Neuroscience, Maastricht University, Maastricht 6229 ER, The Netherlands.ORCID https://orcid.org/0000-0001-8724-3010
Johan GobomClinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal 431 80, Sweden.ORCID https://orcid.org/0000-0001-6193-6193
Lianne M ReusDepartment of Neurology, Alzheimer Center Amsterdam, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam 1081 HZ, The Netherlands.
Valerija DobricicLübeck Interdisciplinary Platform for Genome Analytics, University of Lübeck, Lübeck 23562, Germany.
Mara Ten KateDepartment of Neurology, Alzheimer Center Amsterdam, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam 1081 HZ, The Netherlands.
Suzanne E SchindlerDepartment of Neurology, Washington University School of Medicine, St. Louis, MO 63110, USA.
Inez RamakersDepartment of Psychiatry and Neuropsychology, Alzheimer Centrum Limburg, School for Mental Health and Neuroscience, Maastricht University, Maastricht 6229 ER, The Netherlands.
Betty M TijmsDepartment of Neurology, Alzheimer Center Amsterdam, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam 1081 HZ, The Netherlands.ORCID https://orcid.org/0000-0002-2612-1797
Rik VandenbergheNeurology Service, University Hospitals Leuven, Leuven 3000, Belgium.
Jolien SchaeverbekeNeurology Service, University Hospitals Leuven, Leuven 3000, Belgium.
Pablo Martinez-LageCentre for Research and Memory Clinic, Fundación CITA-Alzhéimer Fundazioa, Donostia-San Sebastián Gipuzkoa 20009, Spain.
Mikel TaintaCentre for Research and Memory Clinic, Fundación CITA-Alzhéimer Fundazioa, Donostia-San Sebastián Gipuzkoa 20009, Spain.
Charlotte E TeunissenDepartment of Clinical Chemistry, Neurochemistry Laboratory, Amsterdam University Medical Centers (AUMC), Amsterdam Neuroscience, Amsterdam 1081 HV, Netherlands.ORCID https://orcid.org/0000-0002-4061-0837
Julius PoppOld Age Psychiatry, University Hospital Lausanne, Lausanne 1005, Switzerland.
Gwendoline PeyratoutOld Age Psychiatry, University Hospital Lausanne, Lausanne 1005, Switzerland.
Magda Tsolaki1st Department of Neurology, AHEPA University Hospital, Medical School, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki 546 36, Greece.
Yvonne Freund-LeviDepartment of Neurobiology, Caring Sciences and Society (NVS), Division of Clinical Geriatrics, Karolinska Institutet, Stockholm 141 57, Sweden.
Simon LovestoneDepartment of Psychiatry, University of Oxford, Oxford OX1 2JD, United Kingdom.
Johannes StrefferDepartment of Biomedical Sciences, Reference Center for Biological Markers of Dementia (BIODEM), University of Antwerp, Antwerp 2610, Belgium.
Frederik BarkhofDepartment of Radiology and Nuclear Medicine, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam 1081 BT, The Netherlands.
Lars BertramLübeck Interdisciplinary Platform for Genome Analytics, University of Lübeck, Lübeck 23562, Germany.ORCID https://orcid.org/0000-0002-0108-124X
Kaj BlennowClinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal 431 80, Sweden.
Henrik ZetterbergClinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal 431 80, Sweden.ORCID https://orcid.org/0000-0003-3930-4354
Pieter Jelle VisserDepartment of Psychiatry and Neuropsychology, Alzheimer Centrum Limburg, School for Mental Health and Neuroscience, Maastricht University, Maastricht 6229 ER, The Netherlands.
Stephanie J B VosDepartment of Psychiatry and Neuropsychology, Alzheimer Centrum Limburg, School for Mental Health and Neuroscience, Maastricht University, Maastricht 6229 ER, The Netherlands.

Funding

Smartphone-Based "Burst" Cognitive AssessmentsP01AG003991 · NIA · WASHINGTON UNIVERSITY · PI CHENGJIE XIONG · 1985 to 2026
$69.5M
The natural history of AB accumulation in preclinical ADP01AG026276 · NIA · WASHINGTON UNIVERSITY · PI MORRIS, JOHN · 2005 to 2025
$49.5M
Research Education ComponentP30AG066444 · NIA · WASHINGTON UNIVERSITY · PI DAVID M. HOLTZMAN · 2020 to 2026
$28.7M
STAGING PRECLINICAL AD WITH CSF BIOMARKERSK23AG053426 · NIA · WASHINGTON UNIVERSITY · PI SCHINDLER, SUZANNE ELIZABETH · 2017 to 2020
$654k
NIA NIH HHS K23 AG053426NIA NIH HHS P01 AG003991NIA NIH HHS P01 AG026276NIA NIH HHS P30 AG066444
6 · The paper itself

Abstract

Suspected non-Alzheimer's disease pathophysiology (SNAP) is a biomarker-based concept describing individuals with abnormal tau and/or neurodegeneration markers but normal amyloid levels. SNAP is common in individuals with normal cognition (NC), but its underlying pathophysiology is understudied, while being relevant for clinical trial design and treatment approaches. We aimed to investigate the pathophysiology of individuals with NC who are amyloid-negative and tau-positive (SNAP) through cerebrospinal fluid (CSF) proteomics. Two hundred and ninety-one individuals with NC were classified based on CSF amyloid β1-42 and phosphorylated tau 181, as amyloid-negative/tau-negative (controls), amyloid-negative/tau-positive (SNAP), amyloid-positive/tau-negative and amyloid-positive/tau-positive. We measured 3102 proteins in CSF using tandem mass tag proteomic analyses. We compared protein abundance between groups using analysis of covariance and identified enriched biological pathways using Gene Ontology. We also examined differences between groups in genetic risk for Alzheimer's disease, estimated using polygenic risk scores based on genome-wide association study data. SNAP individuals with NC showed mostly increased protein levels (

Indexed as

biomarkerscognitively unimpairedproteomicssuspected non-Alzheimer’s disease pathophysiologytau

Identifiers

PMID40641595
PMCPMC12242384

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.